Efficacy and Safety of Gemcabene in Patients With Low HDL-C and Either Normal or Elevated Triglycerides

PHASE2CompletedINTERVENTIONAL
Enrollment

161

Participants

Timeline

Start Date

December 31, 1999

Primary Completion Date

June 30, 2001

Study Completion Date

June 30, 2001

Conditions
HypercholesterolemiaHypertriglyceridemia
Interventions
DRUG

Gemcabene 150 mg

Blinded capsules and tablets, 150 mg, once daily, 84 days

DRUG

Gemcabene 300 mg

Blinded capsules and tablets, 300 mg, once daily, 84 days

DRUG

Gemcabene 600 mg

Blinded capsules and tablets, 600 mg, once daily, 84 days

DRUG

Gemcabene 900 mg

Blinded capsules and tablets, 900 mg, once daily, 84 days

DRUG

Placebo

Blinded capsule and tablets, once daily, 84 days

Sponsors
All Listed Sponsors
lead

NeuroBo Pharmaceuticals Inc.

INDUSTRY